Progress report on new antiepileptic drugs: A summary of the Third Eilat Conference

M. Bialer, S. I. Johannessen, H. J. Kupferberg, R. H. Levy, P. Loiseau, E. Perucca

Research output: Contribution to journalArticlepeer-review


The Third Eilat Conference on New Antiepileptic Drugs was held at the Royal Beach Hotel from May 27 to May 30, 1996. Epileptologists and scientists from 20 countries attended the conference, which was held to discuss critical issues in drug development, new antiepileptic drugs (AEDs) in development, progress reports and recent findings of newly marketed AEDs, the use of AEDs in special populations and their utilization in non-epileptic disorders. Over the last seven years, six new AEDs have been introduced worldwide and new information on their safety and efficacy has become available. These include felbamate, gabapentin, lamotrigine, oxcarbazepine, topiramate and vigabatrin. Drugs in development include those at an advanced stage, such as remacemide and tiagabine, as well as those just entering clinical trials, such as rufinamide (CGP 331010) and levetiracetam (ucb LO59). The following is a summary of the presentations for drugs in development and recent findings on newly marketed drugs.

Original languageEnglish
Pages (from-to)299-319
Number of pages21
JournalEpilepsy Research
Issue number3
Publication statusPublished - Nov 1996


  • antiepileptic drug development
  • clinical trial design
  • drug approval

ASJC Scopus subject areas

  • Clinical Neurology
  • Pediatrics, Perinatology, and Child Health
  • Neurology


Dive into the research topics of 'Progress report on new antiepileptic drugs: A summary of the Third Eilat Conference'. Together they form a unique fingerprint.

Cite this